GlaxoSmithKline Plc
Last updated on 2017-03-21T20:07+0300.
About this image
| Key Titles and Phrases | Count | Lang | Last Seen |
|---|
| Names | Lang | Count |
|---|---|---|
| Glaxosmithkline Plc | EN | 100.00% |
| Type | Entity Name | Count |
|---|---|---|
 | GlaxoSmithKline | 9.02% |
| Inc | 7.41% |
| Pfizer Inc | 4.11% |
| AstraZeneca PLC | 3.21% |
| SA | 2.71% |
| World Health Organization | 2.71% |
| Eli Lilly | 2.61% |
| Reuters Group | 2.40% |
| Novartis | 1.90% |
| Serum Institute | 1.90% |
| Pharmaceuticals Inc | 1.80% |
 | British | 1.50% |
| Joseph Biden | 1.50% |
| Five Forces | 1.20% |
| Jake Sullivan | 1.20% |
| European Union | 1.20% |
| United Nations | 1.10% |
| Bloomberg LP | 1.00% |
| Jeff Zients | 1.00% |
| World Bank | 1.00% |
| International Monetary Fund | 1.00% |
| Monetary Fund | 1.00% |
| Laura Wood | 1.00% |
| Strategy | 1.00% |
| Roche Holding AG | 0.90% |
| Saudi | 0.90% |
| Drug Administration | 0.90% |
| Astellas Pharma | 0.80% |
| Bristol Myers Squibb | 0.80% |
| Abbott Laboratories | 0.80% |
| Type | Entity Name | Score |
|---|---|---|
| GlaxoSmithKline | 0.0781 |
| AstraZeneca PLC | 0.0325 |
| Eli Lilly | 0.0235 |
| Novartis | 0.018 |
| Serum Institute | 0.0177 |
| Pharmaceuticals Inc | 0.0169 |
| SA | 0.0141 |
| Five Forces | 0.0113 |
| Jeff Zients | 0.0101 |
| Inc | 0.0099 |
| Roche Holding AG | 0.0086 |
| Monetary Fund | 0.0084 |
| Laura Wood | 0.0083 |
| Market Development | 0.0083 |
| Product Development | 0.0083 |
| Pfizer Inc | 0.0082 |
| Bloomberg LP | 0.0082 |
| Astellas Pharma | 0.0082 |
| Bristol Myers Squibb | 0.008 |
| International Monetary Fund | 0.0077 |
| Abbott Laboratories | 0.0075 |
| Roche Ltd | 0.0075 |
| Tekmira Pharmaceuticals | 0.0071 |
| Jake Sullivan | 0.0069 |
| David Malpass | 0.0066 |
| Strategy | 0.0061 |
| ASEAN Business | 0.0061 |
| World Bank | 0.006 |
| CSL Ltd | 0.006 |
| Drug Administration | 0.0055 |
Show/hide duplicate news articles.
Show/hide duplicate news articles.
Languages 
Select your languages
Explore Relations
Please send any comments or suggestions to 